Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Nephrology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients
2
Mins
April 2024
In 2022, over 92,000 kidney transplants were performed globally.1 With advancements in transplant science, 1-year graft survival rates…
Read more
2
Mins
4th April 2024
Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients
In 2022, over 92,000 kidney transplants were performed globally.1 With advancements in transplant science, 1-year graft survival rates…
7
Mins
14th March 2024
Sparsentan for treatment of immunoglobulin A nephropathy: Latest study results
In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function
8
Mins
14th March 2024
Renal Replacement Therapy
End-stage liver disease (ESLD) represents a non-reversible, advanced stage of cirrhosis, where the hepatic architecture is distorted and…
8
Mins
7th March 2024
Interview: Smeeta Sinha
Smeeta Sinha National Clinical Director for Renal Medicine, NHS England, UK; Consultant Nephrologist, Northern Care Alliance NHS Foundation…
4
Mins
16th February 2024
Membranous Nephropathy and Pulmonary Tuberculosis
Mycobacterium tuberculosis causing glomerulonephritis (GN) is a rare occurrence, and its association has been seldom reported…
10
Mins
14th December 2023
Current Treatment and Emerging Solutions in IgA Nephropathy
IgAN, which can lead to CKD and kidney failure, is the most common form of primary glomerulonephritis, predominantly…
12
Mins
15th August 2023
Diagnosing Fabry Disease: Practical Clinical Recommendations and Guidance for Patients with Fabry Disease
This article was funded by Sanofi and is intended for healthcare professionals.
10
Mins
27th July 2023
Filling the Gap by Targeting the Gut: First Disease-Modifying Treatment Approved for IgA Nephropathy
Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal…
Loading posts...
1
2
3
…
18
Next »